ADHERENCE WITH PROPHYLACTIC MIGRAINE MEDICATIONS AMONG PATIENTS WITH AND WITHOUT PRIOR PROPHYLACTIC MEDICATION USE

Author(s)

Bonafede MM1, Sapra S2, Tepper SJ3, Cappell KA4, Desai P2
1Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3Dartmouth, Lebanon, NH, USA, 4Truven Health Analytics, an IBM Company, Ann Arbor, MI, USA

OBJECTIVES: To describe adherence and persistence with prophylactic migraine medications (PMM) among all users as well as among subgroups with (Experienced) and without (Naïve) prior PMM use.

METHODS: This retrospective cohort study identified adult migraine patients (ICD-9 346.XX and/or migraine-specific medications) in the Truven Health MarketScan Commercial Database January 2010-June 2014. The first new PMM prescribed in the study period was the index event; patients were stratified based on whether they had pre-index use of a different PMM (PMM Experienced) or were PMM Naïve. Patients without 12 months of enrollment pre- and post-index or with a diagnosis of HIV or malignancy were excluded. The primary study outcomes were adherence and persistence with the index PMM during the 12-month follow-up. Discontinuation was defined as a gap of ≥60 days in supply of the index PMM.

RESULTS:

Conference/Value in Health Info

2017-05, ISPOR 2017, Boston, MA, USA

Value in Health, Vol. 20, No. 5 (May 2017)

Code

PND44

Topic

Patient-Centered Research

Topic Subcategory

Adherence, Persistence, & Compliance

Disease

Neurological Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×